SingleCell Biotechnology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.5M

Overview

SingleCell Biotechnology is an early-stage biotech with a platform technology focused on the most aggressive and treatment-resistant aspects of cancer. Its core innovation is a suite of assays that capture and analyze single cancer stem cells in states of dormancy, migration, and clonogenic growth, providing high-content imaging and downstream multi-omic profiling capabilities. The company, which licensed its foundational technology from UT Southwestern Medical Center, is pre-revenue and actively seeking partnerships with pharmaceutical and research organizations to apply its platform in drug screening and target identification, initially in glioblastoma and breast cancer. Its progress is supported by non-dilutive funding, including a grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Oncology

Technology Platform

Proprietary high-throughput, high-content single-cell phenotyping platform using 3D spatial confinement to assay cancer stem cell states (clonogenicity, migration, dormancy) with downstream retrieval for multi-omic profiling, enabling phenotype-to-genotype mapping.

Funding History

1

Total raised:$2.5M

Seed$2.5MUndisclosedSep 15, 2020

Opportunities

The platform addresses a major bottleneck in oncology drug discovery by targeting dormant and migratory cancer stem cells responsible for recurrence, offering partners a tool to de-risk clinical development.

The growing emphasis on functional precision medicine and complex 3D cell models creates a strong tailwind for adoption of its high-content phenotyping approach.

Non-dilutive grant funding, like the CPRIT award, validates the technology and extends the runway to secure commercial partnerships.

Risk Factors

The company is pre-revenue and faces significant funding risk until it secures major partnership deals.

As a new entrant, it must overcome technology adoption risk, convincing large pharma to switch from established preclinical models.

It operates in a competitive tools landscape and must clearly differentiate its unique phenotype-to-genotype mapping capability.

Competitive Landscape

SingleCell Bio competes with broad single-cell analysis platform companies (e.g., 10x Genomics) and 3D cell culture/organoid providers. Its key differentiation is the proprietary combination of longitudinal 3D phenotyping of specific aggressive cell states with the ability to retrieve those same cells for omics analysis. It faces competition from academic labs and CROs offering specialized migration or clonogenic assays, but few integrate all three phenotypes with downstream molecular profiling in a high-throughput format.

More companies in Diagnostics & Precision Medicine →More companies in United States →